Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Given Average Recommendation of "Moderate Buy" by Analysts

Key Points

• Moderate Buy consensus from eight analysts (5 buy, 2 hold, 1 sell) with an average 12‑month price target of $34.00.
• Q4 results beat estimates — EPS $0.13 vs $0.03 and revenue $129.5M vs $110.8M — but the company remains unprofitable with negative net margin and ROE and a sell‑side forecast of -1.33 EPS for the year.
• Insiders have been net sellers (159,546 shares sold, ~$4.03M in last 90 days), while the stock trades around $24.21 with a market cap of $3.00 billion and a 52‑week range of $11.86–$31.77.

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the eight brokerages that are covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and five have issued a buy recommendation on the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $34.00.

A number of equities research analysts have issued reports on ARQT shares. Guggenheim upped their price target on shares of Arcutis Biotherapeutics from $34.00 to $35.00 and gave the company a "buy" rating in a report on Friday, February 27th. Needham & Company LLC lifted their price objective on Arcutis Biotherapeutics from $31.00 to $36.00 and gave the stock a "buy" rating in a research note on Thursday, February 26th. TD Cowen increased their target price on Arcutis Biotherapeutics from $30.00 to $35.00 and gave the company a "buy" rating in a research note on Thursday, February 26th. Zacks Research lowered Arcutis Biotherapeutics from a "strong-buy" rating to a "hold" rating in a report on Monday, December 29th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Arcutis Biotherapeutics in a research report on Friday, March 27th.

Arcutis Biotherapeutics Price Performance

Shares of Arcutis Biotherapeutics stock opened at $24.21 on Friday. The firm has a fifty day simple moving average of $24.64 and a 200-day simple moving average of $25.23. The company has a current ratio of 3.17, a quick ratio of 2.99 and a debt-to-equity ratio of 0.57. Arcutis Biotherapeutics has a 1-year low of $11.86 and a 1-year high of $31.77. The stock has a market capitalization of $3.00 billion, a price-to-earnings ratio of -172.92 and a beta of 1.76.

Arcutis Biotherapeutics (NASDAQ:ARQT - Get Free Report) last posted its earnings results on Wednesday, February 25th. The company reported $0.13 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.03 by $0.10. Arcutis Biotherapeutics had a negative net margin of 4.29% and a negative return on equity of 10.26%. The business had revenue of $129.50 million for the quarter, compared to analyst estimates of $110.79 million. On average, sell-side analysts expect that Arcutis Biotherapeutics will post -1.33 earnings per share for the current year.

Insiders Place Their Bets

In related news, insider Todd Watanabe sold 37,349 shares of the company's stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $25.18, for a total transaction of $940,447.82. Following the completion of the transaction, the insider directly owned 785,957 shares in the company, valued at $19,790,397.26. This represents a 4.54% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Larry Todd Edwards sold 3,687 shares of the stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $25.18, for a total transaction of $92,838.66. Following the completion of the sale, the insider directly owned 175,178 shares of the company's stock, valued at approximately $4,410,982.04. This trade represents a 2.06% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 159,546 shares of company stock valued at $4,032,162 in the last 90 days. 9.40% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in ARQT. AQR Capital Management LLC grew its position in Arcutis Biotherapeutics by 21.4% during the first quarter. AQR Capital Management LLC now owns 248,196 shares of the company's stock worth $3,882,000 after buying an additional 43,716 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in Arcutis Biotherapeutics by 3.0% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 71,417 shares of the company's stock valued at $1,118,000 after acquiring an additional 2,063 shares in the last quarter. Creative Planning raised its holdings in Arcutis Biotherapeutics by 8.2% in the 2nd quarter. Creative Planning now owns 19,575 shares of the company's stock valued at $274,000 after acquiring an additional 1,477 shares in the last quarter. JPMorgan Chase & Co. lifted its position in shares of Arcutis Biotherapeutics by 1.0% in the 2nd quarter. JPMorgan Chase & Co. now owns 548,789 shares of the company's stock worth $7,694,000 after acquiring an additional 5,407 shares during the period. Finally, Russell Investments Group Ltd. lifted its position in shares of Arcutis Biotherapeutics by 4,562.5% in the 2nd quarter. Russell Investments Group Ltd. now owns 11,190 shares of the company's stock worth $157,000 after acquiring an additional 10,950 shares during the period.

Arcutis Biotherapeutics Company Profile

Arcutis Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for immuno-inflammatory skin diseases. The company's research and development efforts center on targeted treatments that address the underlying biology of conditions such as plaque psoriasis, atopic dermatitis, seborrheic dermatitis and vitiligo. Arcutis employs a precision-medicine approach to deliver topical therapies designed to improve efficacy and tolerability compared with existing treatment options.

In August 2022, Arcutis received U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.